Product category:
Genomics
News Release from: Xantos Biomedicine | Subject: Human cDNA collection
Edited by the Laboratorytalk Editorial
Team on 21 November 2003
Enabling functional genome-wide drug
discovery
Collection of full-length human cDNA clones in mammalian expression vectors to expaned to 35,000, representing one of the world's largest collections
Xantos Biomedicine, a functional biology and drug discovery company, announces that it has expanded its collection of full-length human cDNA clones in mammalian expression vectors to 35,000, representing one of the world's largest collections The Xantos covers individual cDNA expression plasmids from more than 24,000 distinct human gene loci
This article was originally published on Laboratorytalk on 27 Sep 2005 at 8.00am (UK)
Related stories
Screening for a protein with therapeutic relevance
Xantos will identify candidate proteins and analyse their mode of action by combining high throughput and automated overexpression of a human full-length cDNA library with an appropriate assay
Xantos in functional profiling deal with Compugen
Proprietary robotic platform is fully automated cellular gene-transfection and assay system allowing genome-wide screenings for discovery and functional validation of novel targets to be carried out
Redundant clones frequently represent alternate splice products.
Thus the cDNA clones collection comprises a significant portion of the human genome.
It is continually being expanded to represent the entire transcribed human genome.
The collection contains a variety of sub groups relevant for drug development including drugable targets, secreted and receptor proteins.
Furthermore, since sequence information is instantly available it means that cDNAs can be rapidly linked to biological function.
In less than a year Xantos has expanded its clone collection from 20,000 to 35,000, enabling the company to improve the speed and therefore cost with which it can carry out genome-wide functional target identification and validation in XantoScreen.
The entire collection can be screened in less than a month on this automated disease cellular screening platform.
Ulrich Brinkmann, Xantos CSO, commented: "Xantos has already started to reap the benefits from this cDNA collection in its metabolic disease programme, where it has identified a number of novel functionally-validated targets with relevance in diabetes and obesity.
"Likewise a number of unique secreted proteins that play a role in angiogenesis have been identified." Both the Xantos clone collection and disease-specific cDNA libraries are available for use through collaborative partnerships or by customers on a fee-for-service basis.
• Xantos Biomedicine: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
